

You are cordially invited to attend a In-person program entitled:

# Clinical Cases in Polycythemia Vera: When to Intervene with Jakafi® (ruxolitinib) - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

**Tuesday, September 21, 2021 6:30 PM Pacific Standard Time**

*\*The program will begin at 6:30 PM. Please plan to arrive 15 minutes early to sign in.*

## Featured Speaker:

**Rhonda Hewitt, NP**  
Stanford Cancer Center  
San Francisco, CA

## Location:

**Flemings's Prime Steakhouse & Wine Bar**  
180 El Camino Real  
Palo Alto, CA 94304

## REGISTRATION

**Online <http://sphase.info/inc8591>**

*You may also register by contacting your Incyte Representative Steve Wheeler at (650) 906-4745 or [stwheeler@incyte.com](mailto:stwheeler@incyte.com) with the following information: name, title/ degree, state(s) and state license number (s), affiliation, address, phone and email*

**Prior to registering, please review the program title and speaker to ensure you have not attended this program within the past year.**

## INDICATIONS & USAGE

Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Jakafi® (ruxolitinib) is indicated for treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.

Jakafi® (ruxolitinib) is indicated for treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older

**Please see Important Safety Information for Jakafi on back cover and accompanying Full Prescribing Information.**

Please note this program is intended for US healthcare professionals (HCPs) only. This program is sponsored by Incyte Corporation and is not eligible for CE credits.

Consistent with PhRMA guidelines, spouses and other guests of an HCP are not permitted to attend. The cost of meals associated with this event may be disclosed consistent with applicable federal and state law disclosure requirements. State and federal laws and regulations may restrict state or federal employees from receiving meals. By attending this event, you confirm that you have obtained any necessary approvals from your employer. HCPs may be subject to state law restrictions regarding attendance. HCPs licensed in Vermont or employees/agents of Vermont HCPs may not attend this event. Minnesota law restricts Incyte from offering meals or other refreshments to certain HCPs who are licensed in Minnesota and have the ability to prescribe prescription drugs (eg, physicians, physician assistants, nurse practitioners, advanced nurses). If you are licensed to prescribe in Minnesota, please identify yourself on this document and inform an Incyte representative prior to the start of the program.

# IMPORTANT SAFETY INFORMATION

- Treatment with Jakafi® (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
- Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
- Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
- Severe neutropenia ( $ANC < 0.5 \times 10^9/L$ ) was generally reversible by withholding Jakafi until recovery
- Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines
- Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
- Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
- Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
- Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
- When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
- Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
- Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
- In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence  $\geq 15\%$ ) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence  $> 50\%$ ) were infections and edema
- Dose modifications may be required when administering Jakafi with strong CYP3A4 inhibitors or fluconazole or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
- Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose

Please see accompanying Full Prescribing Information for Jakafi.